Knight Therapeutics Inc
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for p… Read more
Knight Therapeutics Inc (KHTRF) - Total Assets
Latest total assets as of September 2025: $1.05 Billion USD
Based on the latest financial reports, Knight Therapeutics Inc (KHTRF) holds total assets worth $1.05 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Knight Therapeutics Inc - Total Assets Trend (2013–2024)
This chart illustrates how Knight Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Knight Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Knight Therapeutics Inc's total assets of $1.05 Billion consist of 41.2% current assets and 58.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.3% |
| Accounts Receivable | $113.53 Million | 11.8% |
| Inventory | $102.70 Million | 10.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $283.61 Million | 29.4% |
| Goodwill | $86.48 Million | 9.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Knight Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Knight Therapeutics Inc's current assets represent 41.2% of total assets in 2024, a decrease from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2024, down from 100.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 29.4% of total assets.
Knight Therapeutics Inc Competitors by Total Assets
Key competitors of Knight Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Knight Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Knight Therapeutics Inc generates 0.39x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Knight Therapeutics Inc generates $ 0.45 in net profit.
Knight Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.62 | 3.36 | 4.86 |
| Quick Ratio | 1.68 | 2.39 | 4.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $248.37 Million | $ 279.41 Million | $ 440.58 Million |
Knight Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Knight Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.81 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | 1.9% |
| Total Assets | $963.80 Million |
| Market Capitalization | $270.15 Million USD |
Valuation Analysis
Below Book Valuation: The market values Knight Therapeutics Inc's assets below their book value (0.28 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Knight Therapeutics Inc's assets grew by 1.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Knight Therapeutics Inc (2013–2024)
The table below shows the annual total assets of Knight Therapeutics Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $963.80 Million | +1.94% |
| 2023-12-31 | $945.49 Million | -10.37% |
| 2022-12-31 | $1.05 Billion | +6.35% |
| 2021-12-31 | $991.89 Million | -4.60% |
| 2020-12-31 | $1.04 Billion | -20.35% |
| 2019-12-31 | $1.31 Billion | +24.10% |
| 2018-12-31 | $1.05 Billion | +4.56% |
| 2017-12-31 | $1.01 Billion | +1.54% |
| 2016-12-31 | $990.77 Million | +52.66% |
| 2015-12-31 | $648.99 Million | +33.37% |
| 2014-12-31 | $486.61 Million | +48661317000.00% |
| 2013-12-31 | $1.00 | -- |